pDBD * 4R9

General Information


DRACP ID  DRACP01752

Peptide Name   pDBD * 4R9

Sequence  YLCAGRNDCIIAIKFEEKTAQHAAIENVFRLERRRRRRRRR

Sequence Length  41

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetics

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
ICR27-4 Human leukemic Leukemia As show in fig1, data show a significant anticancer effect WST-1 assay 4 h Patent
CCRF-CEM Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia Leukemia As show in fig1, data show a significant anticancer effect WST-1 assay 4 h Patent
MCF-7 Invasive breast carcinoma of no special type Carcinoma As show in fig1, data show a significant anticancer effect WST-1 assay 4 h Patent
CaCo-2 Colon adenocarcinoma Carcinoma As show in fig1, data show a significant anticancer effect WST-1 assay 4 h Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  NIH 3T3: Barely toxic

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01752

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C216H365N81O57S2

Absent amino acids  MPSW

Common amino acids  R

Mass  578655

Pl  11.89

Basic residues  14

Acidic residues  5

Hydrophobic residues  14

Net charge  9

Boman Index  -18530

Hydrophobicity  -101.22

Aliphatic Index  76.34

Half Life 
  Mammalian: 2.8 hour
  Yeast: 10 min
  E.coli: 2 min

Extinction Coefficient cystines  1615

Absorbance 280nm  40.38

Polar residues  7

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US2006/0100147A1

Patent Title  Anticancer peptide

Other Iinformation  Patent Application; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Discontinued; Application No: 23095205; Filed: Sep 19, 2005; Published: May 11, 2006; Earliest Priority: Sep 20, 2004

Other Published ID  US2009203594A1 




DRACP is developed by Dr.Zheng's team.